Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers

OBJECTIVE: Bevacizumab was recently approved by the US Food and Drug Administration for use in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) when no more than two prior cytotoxic regimens have been used; due to concerns...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Gynecol Oncol
Main Authors: Martin, Jovana Y., Urban, Renata R., Liao, John B., Goff, Barbara A.
Formato: Artigo
Idioma:Inglês
Publicado em: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4944014/
https://ncbi.nlm.nih.gov/pubmed/27329195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3802/jgo.2016.27.e47
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados